Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 124655-17-0 | MDL No. : | MFCD00065575 |
Formula : | C11H21NO4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | LRFZIPCTFBPFLX-ZETCQYMHSA-N |
M.W : | 231.29 | Pubchem ID : | 7005057 |
Synonyms : |
Boc-D-tert-leucine
|
Num. heavy atoms : | 16 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.82 |
Num. rotatable bonds : | 6 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 61.02 |
TPSA : | 75.63 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.09 cm/s |
Log Po/w (iLOGP) : | 2.26 |
Log Po/w (XLOGP3) : | 2.28 |
Log Po/w (WLOGP) : | 2.01 |
Log Po/w (MLOGP) : | 1.42 |
Log Po/w (SILICOS-IT) : | 0.75 |
Consensus Log Po/w : | 1.74 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -2.31 |
Solubility : | 1.12 mg/ml ; 0.00485 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.51 |
Solubility : | 0.0722 mg/ml ; 0.000312 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.47 |
Solubility : | 7.8 mg/ml ; 0.0337 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.81 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
83% | With sodium hydroxide In methanol; water at 0 - 20℃; | Intermediate 95To a solution of 3-methyl-D-valine (900 mg, 6.86 mmol) in 7 mL of 1 M aqueous sodium hydroxide and 7 mL of methanol was added Boc-anhydride (1 .797 g, 8.23 mmol) at 0°C. The reaction mixture was warmed to room temperature and stirred overnight. After most of the methanol was evaporated, the solution was acidified to pH 2 with an aqueous solution of HCI (1 M) and extracted 3 times with ethylacetate (3 x 20 mL). The organic layers were combined and washed with brine (2 x 5mL). Evaporation of the solvent afforded the title compound as a white solid with a 83percent yield(1.36 g).H NMR (400 MHz, DMSO-c/6): δ ppm 12.44 (1 H, s), 6.82 (1 H, d), 3.76 (1 H, d), 1.38 (9H, (9H, s); UPLC: 0.64 min, 232 [M+H]+ |
1.36 g | With sodium hydroxide In methanol; water at 0 - 20℃; | Intermediate 76 N-[(1,1-dimethylethyl)oxy]carbonyl}-3-methyl-D-valine [0708] [0709] To a solution of 3-methyl-D-valine (900 mg, 6.86 mmol) in 7 ml of 1 M aqueous sodium hydroxide and 7 ml of methanol was added Boc-anhydride (1.797 g, 8.23 mmol) at 0° C. The reaction mixture was warmed to room temperature and stirred overnight. After most of the methanol was evaporated, the solution was acidified to pH 2 with an aqueous solution of HCl (1M) and extracted 3 times with ethylacetate (3×20 ml). The organic layers were combined and washed with brine (2×5 ml). Evaporation of the solvent afforded the title compound as a white solid (1.36 g). [0710] 1H NMR (400 MHz, DMSO-d6): δ ppm 12.44 (1H, s), 6.82 (1H, d), 3.76 (1H, d), 1.38 (9H, s), 0.93 (9H, s); UPLC: 0.64 min, 232 [M+H]+ |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
64% | With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 20℃; for 18.5h; | Compound 14 <n="469"/>To a solution of Boc-D-tert-leucine (121.7 mg, 0.526 mmol), purchased from Bachem, in DMF (2 mL) at r.t. were added EDC (463.1 mg, 1.56 mmol) and HOBT (71.1 mg, 0.526 mmol) and the reaction mixture was stirred for 30 min. Then a solution of Example G (210 mg, 0.40 mmol) in DMP (2 mL) was added to the reaction mixture after the addition of 4-methylmorpholine ("NMM") (0.26 mL, 2.34 mmol). The reaction was stirred at r.t. for 18 h and then the reaction was diluted with ethyl acetate and washed with saturated NaHCO3 and brine before it was dried over Na2SO4, and concentrated. The crude residue was purified using silica gel chromatography (0-10% methanol/DCM), and again using silica gel chromatography (25-75% ethyl acetate /hexane) and yielded Compound 14 as a solid (189.9 mg, 0.260 mmol, 64%). Mass spectrum: (M+H)+ = 732.2. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With caesium carbonate; In ethanol; for 0.75h; | Example 2; Preparation of N-[(2S)-3-amino-2-hydroxypropyl]-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl]benzamide (Compound 175); Step A: Keto-Ester Synthesis; A stirred solution of the appropriate N-Boc-acid (4.0 mmol), compound 2-1, tert-butyl glycine, in EtOH (10 ml) was treated with Cs2CO3 (2.0 mmol). After 45 min, the EtOH was removed by evaporation under reduced pressure. The residual cesium salt was re-dissolved in DMF (15 ml) and the treated with the appropriate alpha-halo-ketone, eg, 2-bromoacetophenone (4.0 mmol) and stirred at r.t. until the reaction was complete. The reaction mixture was then partitioned between EtOAc and H2O, and the organics separated, then washed with H2O (×3), brine (×3), then dried (Na2SO4), filtered, and evaporated under reduced pressure to give the keto-ester 2-2 which was pure enough to use directly in the next step. | |
With caesium carbonate; In ethanol; for 0.75h; | Example 1 Preparation of N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl]-N-[(3S)-3-fluoropyrrolidin-3-yl]methyl}-1,4'-bipiperidine-1'-carboxamide (76) and N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl]-N-[(3R)-3-fluoropyrrolidin-3-yl]methyl}-1,4'-bipiperidine-1'-carboxamide (77) Step A: Keto Ester Synthesis A stirred 0.4 M solution of the appropriate N-Boc-acid (1 eq.), e.g., tert-butyl leucine 1-1 in EtOH, was treated with Cs2CO3 (0.5 eq.). After 45 min, the EtOH was removed by evaporation under reduced pressure. The residual cesium salt was re-dissolved in DMF (1.5× volume of DMF used in the reaction) and then treated with the appropriate alpha-halo-ketone, e.g., 2-bromoacetophenone (1 eq.) and stirred at RT until the reaction was complete. The reaction mixture was then partitioned between EtOAc and H2O, and the organics separated, then washed with H2O (×3), brine (×3), then dried (Na2SO4), filtered, and evaporated under reduced pressure to give the keto ester 1-2 which was pure enough to use directly in the next step. ; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
66% | With benzotriazol-1-ol; 1,8-diazabicyclo[5.4.0]undec-7-ene; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In acetonitrile; for 15h; | To a solution of Boc-D-tert-leucine (0.69 g), HOBt (0.69 g) and WSC (0.86 g) in acetonitrile (20 ml) was added a solution of 5-methyl-2-(4-piperidinylmethyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one dihydrochloride (0.91 g) as described above, DBU (0.6 ml) and triethylamine (0.61 ml) in acetonitrile (20 ml), and mixed for 15 hours. The solvent was distilled off under reduced pressure, and the residue was dissolved in dichloromethane. The dichloromethane solution was washed with an aqueous sodium hydrogen carbonate solution and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified with basic silica gel column (ethyl acetate/methanol = 10/1) to obtain the title compound as colorless powder (1.2 g, 66%). NMR (CDCl3) delta:0.96 (9H, s), 1.42 (9H, s), 1.60-2.00 (4H, m), 2.50-2.70 (1H, m), 2.60 (3H, s), 3.00-3.10 (1H, m), 3.29-3.44 (3H, m), 4.11-4.18 (1H, m), 4.35 (2H, s), 4.50-4.72 (2H, m), 5.35 (1H, J=9.0), 6.70 (1H, s). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In dichloromethane; | Step 1: (R)-tert-butyl 1-(4-(3,4-dichlorophenyl)piperazin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate To a mixture of N-Boc-D-alpha-tert-butylglycine (620 mg, 2.68 mmol). TEA (0.27 mL, 2.68 mmol), HOBt (370 mg, 2.68 mmol), 4-(3,4-dichlorophenyl)piperazine (619 mg, 2.68 mmol) and EDC (515 mg, 2.68 mmol) was added dichloromethane. Upon completion of addition, the resulting solution was allowed to stir overnight. After this time, the resulting solution was filtered though a silica gel pad and washed with ethyl acetate/hexanes. The filtrate was evaporated to provide (R)-tert-butyl 1-(4-(3,4-dichlorophenyl)piperazin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate as a crude solid which was used directly in the next step. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With triethylamine; In tetrahydrofuran; at -5 - 0℃; for 0.5h; | Step C: Acylation of Hydrazide:1-3 1-4 1-5 The <strong>[124655-17-0]N-Boc-D-tert-butylglycine</strong> 1-3 (2 mmol) was converted to a mixed anhydride by adding ethyl chloroformate (2.4 mmol), Et3N (3 mmol) in dry THF at -50C to 00C. The mixture was stirred at -50C for 30 min. The resulting solid was filtered off. Add additional dry THF to wash the precipitate. The resulting reaction solution was added to a THF solution of hydrazide (1-3, 2 mmol) at -5C. Then the reaction was stirred and gradually warmed to RT overnight. Once the reaction was complete, the mixture was partitioned between EtOAc and H2O. The organic layer was separated and washed with H2O (x3), sat. brine (x3), then dried (Na2SO4), filtered, and evaporated under reduced pressure to give the crude product, which was purified on silica gel column (Hexane/Ethyl acetate) to afford 1- 5. (Yield 67%) | |
With triethylamine; In tetrahydrofuran; at -5 - 0℃; for 0.5h; | Acylation of 2,5-difluorobenzimidohydrazide; The <strong>[124655-17-0]N-Boc-D-tert-butylglycine</strong> (7.5 g, 32.4 mmol) was converted to a mixed anhydride by adding ethyl chloroformate (3.41 mL, 35.6 mmol), Et3N (6.8 mL, 48.6 mmol) in anhydrous THF (65 mL, 0.5 M) at -5 C. to 0 C. The mixture was stirred at -5 C. for 30 min. The resulting solid was filtered off and additional anhydrous THF was added to wash the precipitate. The resulting reaction solution was then added to a THF solution of 2,5-difluorobenzimido-hydrazide (5.53 g, 32.4 mmol) at -5 C. Then the reaction was gradually warmed to room temperature and stirred for overnight. Once the reaction was complete, the mixture was partitioned between EtOAc and H2O. The organic layer was separated and washed with H2O, brine, then dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure to give the crude product, which was purified on silica gel column (50% EtOAc in Hexanes) to afford (R)-tert-butyl 1-(2-((2,5-difluorophenyl)(imino)methyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (67%). Rf=0.4 (50% EtOAc in Hexanes). LC/MS (uplc): MH+ 385.3, 0.65 min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In ethanol; for 0.75h; | Step A; Lambda Lambda 1 "2A stirred solution of the appropriate N-Boc-acid (4.0 mmol), e.g., tert -butyl leucine 1-1, in EtOH (10 mL) was treated with Cs2CO3 (2.0 mmol). After 45 min, the EtOH was removed by evaporation under reduced pressure. The residual cesium salt was re-dissolved in DMF (15 mL) and then treated with the appropriate alpha-halo-ketone, e.g., 2- bromoacetophenone (4.0 mmol) and stirred at RT until the reaction was complete. The reaction mixture was then partitioned between EtOAc and H2O, and the organics separated, then washed with H2O (x3), brine (x3), then dried (Na2SO4), filtered, and evaporated under reduced pressure to give the keto ester 1-2 which was pure enough to use directly in the next step. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
96% | Step A: Preparation of Compound 2-3; To a 5-necked flask containing 1 eq. of Compound 2-1 was added 0.7 eq. OfK2CO3 to give a 0.25M solution OfK2CO3 in acetone. After being stirred under N2 for 45 minutes, 1.0 eq. of Compound 2-2 in 1 M of acetone was added followed by addition of 0.2 eq. of KI in 5 M acetone. When the reaction is completed (about 3 hours), the reaction mixture was <n="54"/>cooled with an ice bath. Ice water (equal to approximately 2.5 X volume of acetone used in reaction) was added via addition funnel at such a speed that the temperature did not exceed 15 0C. After being stirred in an ice bath for one hour, the product was collected by vacuum filtration. The filter cake was washed 3 times with 20% acetone and 3 times with water. The filter cake was air-dried and further dried in an oven at 50C/5 torr until a consistent weight is reached. Yield 92.7 g (96%). HPLC purity: 99%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
77% | Step 1: Preparation of(R)-tert-butyl3,3-dimethyl-1-(methylamino)-1-oxobutan-2-ylcarbamate (Intermediate 30A). To a cold solution of <strong>[124655-17-0](R)-2-(tert-butoxycarbonylamino)-3,3-dimethylbutanoic acid</strong> (0.50 g, 2.16 mmol) in acetonitrile (8 mL) was added methylamine hydrochloride (0.48 g, 7.13 mmol), followed by DIEA (1.67 g, 12.9 mmol). The resulting mixture was stirred for 20 min and TBTU (0.76 g, 2.37 mmol) was added and the stirring continued overnight. The mixture was concentrated, diluted with EtOAc (30 mL) and washed successively with aqueous 5% KHSO4, saturated NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to provide Intermediate 30A (0.41 g, 77%). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
83% | With sodium hydroxide; In methanol; water; at 0 - 20℃; | Intermediate 95To a solution of <strong>[26782-71-8]3-methyl-D-valine</strong> (900 mg, 6.86 mmol) in 7 mL of 1 M aqueous sodium hydroxide and 7 mL of methanol was added Boc-anhydride (1 .797 g, 8.23 mmol) at 0C. The reaction mixture was warmed to room temperature and stirred overnight. After most of the methanol was evaporated, the solution was acidified to pH 2 with an aqueous solution of HCI (1 M) and extracted 3 times with ethylacetate (3 x 20 mL). The organic layers were combined and washed with brine (2 x 5mL). Evaporation of the solvent afforded the title compound as a white solid with a 83% yield(1.36 g).H NMR (400 MHz, DMSO-c/6): delta ppm 12.44 (1 H, s), 6.82 (1 H, d), 3.76 (1 H, d), 1.38 (9H, (9H, s); UPLC: 0.64 min, 232 [M+H]+ |
Intermediate 76/V-[(l,l-dimethylethyl)oxylcarbonyl}-<strong>[26782-71-8]3-methyl-D-valine</strong>To a solution of <strong>[26782-71-8]3-methyl-D-valine</strong> (900 mg, 6.86 mmol) in 7 ml of 1 M aqueous sodium hydroxide and 7 ml of methanol was added Boc-anhydride (1.797 g, 8.23 mmol) at 0C. The reaction mixture was warmed to room temperature and stirred overnight. After most of the methanol was evaporated, the solution was acidified to pH 2 with an aqueous solution of HCI (1M) and extracted 3 times with ethylacetate (3 x 20 ml). The organic layers were combined and washed with brine (2 x 5ml).Evaporation of the solvent afforded the title compound as a white solid (1.36 g). XH NMR (400 MHz, DMSO-d6): delta ppm 12.44 (IH, s), 6.82 (IH, d), 3.76 (IH, d), 1.38 (9H, s), 0.93 (9H, s); UPLC: 0.64 min, 232 [M+H]+ | ||
1.36 g | With sodium hydroxide; In methanol; water; at 0 - 20℃; | Intermediate 76 N-[(1,1-dimethylethyl)oxy]carbonyl}-<strong>[26782-71-8]3-methyl-D-valine</strong> [0708] [0709] To a solution of <strong>[26782-71-8]3-methyl-D-valine</strong> (900 mg, 6.86 mmol) in 7 ml of 1 M aqueous sodium hydroxide and 7 ml of methanol was added Boc-anhydride (1.797 g, 8.23 mmol) at 0 C. The reaction mixture was warmed to room temperature and stirred overnight. After most of the methanol was evaporated, the solution was acidified to pH 2 with an aqueous solution of HCl (1M) and extracted 3 times with ethylacetate (3×20 ml). The organic layers were combined and washed with brine (2×5 ml). Evaporation of the solvent afforded the title compound as a white solid (1.36 g). [0710] 1H NMR (400 MHz, DMSO-d6): delta ppm 12.44 (1H, s), 6.82 (1H, d), 3.76 (1H, d), 1.38 (9H, s), 0.93 (9H, s); UPLC: 0.64 min, 232 [M+H]+ |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
90% | 114c) tert-butyl ((1R)-2,2-dimethyl-1-((4-(2-methyl-4-pyridinyl)-1-piperazinyl)carbonyl)propyl)carbamate To a solution of Boc-D-tert-leucine (0.23 g) in methylene chloride (5 ml) were added HOBt (0.20 g), WSC (0.29 g) and triethylamine (0.28 ml) under ice-cooling, and the reaction mixture was mixed at 0C for 15 minutes. Then, 1-(2-methyl-4-pyridinyl)piperazine (0.18 g) obtained in Example 114b) was added thereto, and further mixed at room temperature for 13 hours. The solvent was distilled off under reduced pressure, and the residue was dissolved in ethyl acetate. The reaction mixture was washed with an aqueous potassium carbonate solution and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and then the residue was purified with basic silica gel column (ethyl acetate) to obtain the title compound as a colorless solid (0.35 g, 90%). NMR (CDCl3) delta: 1.00 (9H, s), 1.43 (9H, s), 2.47 (3H, s), 3.20-3.50 (4H, m), 3.58-3.80 (2H, m), 3.82-3.98 (2H, m), 4.52 (1H, d, J=10.2), 5.31 (1H, d, J=10.2), 6.49-6.53 (2H, m), 8.21 (1H, d, J=5.8). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
133b) N-(4-chlorophenyl)-N'-((1R)-2,2-dimethyl-1-((4-(2-((2Z)-2-(methylimino)-1,3-thiazol-3(2H)-yl)ethyl)-1-piperidinyl)carbonyl)propyl)urea hydrochloride To tert-butyl 4-(2-((2Z)-2-(methylimino)-1,3-thiazol-3(2H)-yl)ethyl)-1-piperidinecarboxylate (1.3 g) obtained in Example 133a) was added concentrated hydrochloric acid (2 ml), subsequently, the mixture was diluted with ethanol, and then concentrated under reduced pressure. to the residue was added triethylamine (1.7 ml) and dissolved in acetonitrile (20 ml). WSC (1.1 g), HOBt (0.90 g) and Boc-D-tert-leucine (1.4 g) were added thereto, and mixed at room temperature for 12 hours. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in chloroform and a saturated aqueous sodium hydrogen carbonate solution. The organic layer was collected by separation and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. To the residue was added trifluoroacetic acid (10 ml), and mixed for 30 minutes. The reaction mixture was poured into chloroform and a saturated aqueous sodium hydrogen carbonate solution, and the isolated organic layer was collected by separation. The organic layer was dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was dissolved in acetonitrile, 4-chlorophenyl isocyanate (0.60 g) was added thereto, and mixed for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified with silica gel column to obtain N-(4-chlorophenyl)-N'-((1R)-2,2-dimethyl-1-((4-(2-((2Z)-2-(methylimino)-1,3-thiazol-3(2H)-yl)ethyl)-1-piperidinyl)carbonyl)propyl)urea as a white solid (0.98 g, 47%). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
50% | 139c) allyl (2Z)-3-(1-(2-(N'-(4-chlorophenyl)ureido)-3,3-dimethylbutyroyl)-4-piperidinyl)methyl-1,3-thiazol-2(3H)-ylidenecarbamate tert-Butyl 4-(((2Z)-2-(((allyloxy)carbonyl)imino)-1,3-thiazol-3(2H)-yl)methyl)-1-piperidinecarboxylate (0.49 g) obtained in Example 139b) was dissolved in a 4 N solution of hydrochloric acid in dioxane (10 ml), and mixed at room temperature for 4 hours. To the reaction mixture was added an aqueous potassium carbonate solution and extracted with chloroform. The extract was dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was dissolved in acetonitrile, triethylamine (0.36 ml), WSC (0.37 g), HOBt (0.29 g) and Boc-D-tert-leucine (0.44 g) were added thereto, and mixed at room temperature for 12 hours. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in chloroform and a saturated aqueous sodium hydrogen carbonate solution. The organic layer was collected by separation and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was dissolved in a 4 N solution of hydrochloric acid in dioxane and mixed at room temperature for 4 hours. To the reaction mixture was added an aqueous potassium carbonate solution and extracted with chloroform. The extract was dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was dissolved in acetonitrile, 4-chlorophenyl isocyanate was added thereto, and mixed for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified with silica gel column to obtain the title compound as a white solid (0.35 g, 50%). NMR (CDCl3) delta: 0.96-1.08 (9H, m), 1.20-1.35 (2H, m), 1.63-1.79 (2H, m), 2.29 (1H, m), 2.55 (1H, m), 3.03 (1H, m), 3.85 (1H, m), 4.03 (1H, d, J=7.7), 4.22 (1H, m), 4.61-4.74 (3H, m), 4.87 (1H, t, J=9.8), 5.23 (1H, d, J=10.4), 5.35 (1H, d, J=17.2), 6.06 (1H, m), 6.59-6.84 (2H, m), 7.16-7.23 (4H, m). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | 98a) tert-butyl (1R)-2,2-dimethyl-1-((4-(1-methyl-4-piperidinyl)-1-piperazinyl)carbonyl)propylcarbamate To a solution of Boc-D-tert-leucine (0.46 g) and HOBt (0.46 g) in acetonitrile (20 ml) was added WSC (0.58 g), and the reaction mixture was mixed at room temperature for 15 minutes. Then, 1-(1-methyl-4-piperidyl)piperazine (0.70 g) and triethylamine (0.61 g) were added, and the reaction mixture was mixed at room temperature for 15 hours. The solvent was distilled off under reduced pressure, and the residue was dissolved in ethyl acetate. The ethyl acetate solution was washed with an aqueous sodium hydrogen carbonate solution and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to obtain the title compound as a colorless oil (0.80 g, quantitative). NMR (CDCl3) delta: 0.97 (9H, m), 1.43 (9H, s), 1.58-1.64 (2H, m), 1.89-1.97 (2H, m), 2.23-2.26 (3H, m), 2.32-2.58 (5H, m), 2.88-2.92 (2H, m), 3.20-3.29 (2H, m), 3.45-3.58 (2H, m), 3.67-3.83 (2H, m), 4.49-4.52 (1H, m), 5.34-5.37 (1H, m). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
92% | 19a) tert-butyl (1R)-2,2-dimethyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl)carbonyl)propylcarbamate To a solution of Boc-D-tert-leucine (0.23 g) and HOBt (0.23 g) in acetonitrile (5 ml) was added WSC (0.29 g), and the reaction mixture was mixed at room temperature for 15 minutes. Then, a solution of 5-methyl-2-(4-piperidinyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one dihydrochloride (0.29 g), DBU (0.30 g) and triethylamine (0.30 g) in acetonitrile (5 ml) was added thereto. The reaction mixture was mixed at room temperature for 15 hours, the solvent was then distilled off under reduced pressure, and the residue was dissolved in ethyl acetate. The ethyl acetate solution was washed with an aqueous sodium hydrogen carbonate solution and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified with basic silica gel column (ethyl acetate to ethyl acetate/methanol = 5/1) to obtain the title compound as colorless powder (0.40 g, 92%). NMR (CDCl3) delta: 0.98-1.01 (9H, m), 1.43-1.45 (9H, m), 1.61-1.95 (4H, m), 2.59-2.72 (1H, m), 2.61 (3H, s), 3.14-3.22 (1H, m), 4.20-4.29 (4H, m), 4.51-4.55 (1H, m), 4.80-4.85 (1H, m), 5.31-5.34 (1H, m), 6.70-6.71 (1H, m). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
75% | 96c) tert-butyl (1R)-2,2-dimethyl-1-((4-(2-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2-yl)ethyl)-1-piperidinyl)carbonyl)propylcarbamate To a solution of Boc-D-tert-leucine (0.69 g) in methylene chloride (15 ml) were added HOBt (0.61 g), WSC (0.86 g) and triethylamine (0.84 ml) under ice-cooling. The reaction mixture was mixed at 0C for 2.5 hours. Then, 5-methyl-2-(2-(4-piperidinyl)ethyl)-1,2-dihydroimidazo[1,5-c]imidazol-3-one (0.74 g) obtained in Example 96b) was added thereto, and further mixed at room temperature for 15 hours. The solvent was distilled off under reduced pressure, and the residue was dissolved in ethyl acetate. The ethyl acetate solution was washed with an aqueous sodium hydrogen carbonate solution and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified with silica gel column (ethyl acetate/methanol = 20/1) to obtain the title compound as colorless powder (0.95 g, 69%). NMR (CDCl3) delta: 0.96-0.99 (9H, m), 1.10-1.34 (2H, m), 1.42-1.43 (9H, m), 1.56-1.60 (3H, m), 1.75-1.92 (2H, m), 2.51-2.66 (4H, m), 2.97-3.16 (1H, m), 3.48-3.54 (2H, t, J=5.9), 4.08-4.18 (1H, m), 4.31 (2H, s), 4.50-4.72 (2H, m), 5.33-5.37 (1H, m), 6.70 (1H, m). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
79% | 97d) tert-butyl (1R)-2,2-dimethyl-1-(4-(2-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2-yl)ethyl)-1-piperazinyl)carbonyl)propylcarbamate To a solution of Boc-D-tert-leucine (93 mg) in methylene chloride (2 ml) were added HOBt (81 mg), WSC (114 mg) and triethylamine (0.11 ml) under ice-cooling, and the reaction mixture was mixed at 0C for 30 minutes. Then, a solution of 5-methyl-2-(2-(1-piperazinyl)ethyl)-1,2-dihydroimidazo[1,5-c]imidazol-3-one (0.10 g) obtained in Example 97c) in methylene chloride (3 ml) was added, and further mixed at room temperature for 15 hours. The solvent was distilled off under reduced pressure, and the residue was dissolved in ethyl acetate. The ethyl acetate solution was washed with an aqueous potassium carbonate solution and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified with basic silica gel column (ethyl acetate/methanol =30/1) to obtain the title compound as a colorless oil (0.15 g, 79%). NMR (CDCl3) delta: 0.97 (9H, s), 1.43 (9H, s), 2.4-2.7 (9H, m), 3.40-3.85 (6H, m), 4.43 (2H, s), 4.49 (1H, d, J=10.2), 5.25-5.40 (1H, br), 6.69 (1H, s). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetonitrile; at 0 - 20℃; for 3h; | PREPARATION W: (i?)-3,3-dimethyl-2-(3-oxopyrrolo[4,3,2- de] [2,6]naphthyridin-4( l/f,3/f,5H)-yl)butanoic acid[0521] STEP A: (i?)-benzyl 2-amino-3,3-dimethylbutanoate, TFA salt[0522] Benzyl bromide (2.26 mL, 19.0 mmol) was added to a stirred solution of (R)-2- (tert-butoxycarbonylamino)-3-3-dimethylbutanoic acid (4.0 g, 17.3 mmol) in AcCN (80 mL) at 0 0C. DBU (3.13 mL, 20.8 mmol) was added slowly, and the solution was stirred for 3 h while warming to room temperature. The solution was concentrated in vacuo, taken up in EtOAc, and washed with aqueous HCl (IN), aqueous NaHCO3 (sat.), and brine. The organics were dried over MgSO4) and concentrated. The resulting clear oil was dissolved in TFA/DCM (50%, 16 mL) and stirred for 1 h at room temperature. The solution was concentrated and purified by short silica column (10% MeOH/DCM) to give the title compound as a white powder (5.02 g, 87%). 1H NMR (500 MHz, DMSO-J6) delta 1.05 (s, 9H), 3.72 (s, IH), 5.17 (AB q, J=40.0, 12.0 Hz, 2H), 7.25-7.35 (m, 5H), 8.20 (br s, 2H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Intermediate 961 -dimethylethyl((1 ?)-2,2-dimethyl-1-(r(6-(r4-methyl-3-(methyloxy)phenylloxy -3-To a solution of N-[(1 ,1-dimethylethyl)oxy]carbonyl}-3-methyl-D-valine (Intermediate 95, 20.1 mg) in dry N.Ndimethylformamide (1 mL), DIPEA (0.015 mL, 0.087 mmol) and then HATU (38.0 mg, 0.100 mmol) were added and the reaction mixture was stirred for 15 minutes at room temperature under argon. Then 6-[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinamine (Intermediate 50, 10 mg) was added and the reaction mixture was stirred at 50C under argon 3 hours. The reaction was left at room temperature overnight. The reaction mixture was evaporated. The residue obtained was dissolved in dichloromethane. The organic phase was washed with brine and then with a saturated aqueous solution of NaHC03. It was then dried over sodium sulphate. The residue obtained was purified on silica gel (Companion instrument) with cyclohexane/ ethylacetate as eluents from 100/0 to 70/30. This afforded the title compound (9.2 mg).H NMR (400 MHz, CDCI3) : delta ppm 8.53 (1 H, s), 8.21 (1 H, d), 7.87 (1 H, d), 7.09 (1 H, d),6.76 (1 H, d), 6.59 (2H, m), 5.43 (1 H, d), 4.10 (1 H, d), 3.75 (3H, s), 2.17 (3H, s), 1.42 (9H, s), 1.07 (9H, s); UPLCjpqc: 0.87 min, 444 [M+H]+ |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: At first, (1R,2R)-1,2-diaminocyclohexane 2 (2.28 g, 20 mmol) was added to dichloromethane. The mixture was cooled to 0 C and a solution of acetyl chloride/tosyl chloride (6.7 mmol) in 10 mL of dichloromethane was added dropwise over 30 min. After the addition was complete, the mixture was allowed to warm to room temperature and stirred overnight. The resulting solution was washed with water and the solvent was removed at reduced pressure. The residue was purified through column chromatography on silica gel (eluent, ethyl acetate/methanol 3:1) to give the mono-substituted aminocyclohexane 3. The corresponding amino acid (15 mmol) and N,N'-dicyclohexylcarbodiimide (DCC) (3.11 g, 15 mmol) were dissolved in dichloromethane (30 mL) and cooled to 0 C. After the solution was stirred for 30 min, a solution of 3 (10 mmol) in 20 mL dichloromethane was added dropwise over 15 min. After the addition was complete, the mixture was warmed to room temperature and stirred for another 12 h. After filtration and removal of solvent at reduced pressure, the residue was purified by flash column chromatography on silica gel (eluent, hexane/ethyl acetate 2:1) to provide the protected catalyst, which was dissolved (8 mmol) in a mixture of TFA/CH2Cl2 30% (20 mL), and stirred for 12 h at room temperature. The mixture was made basic by the addition of sodium bicarbonate and after filtration, the solvent was removed at reduced pressure and was purified through flash column chromatography on silica gel (eluent, ethyl acetate/methanol 5:1) to yield the catalysts 1 shown in Table 1. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
97% | With benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; | Step 1 A round-bottomed flask was charged with Boc-D-tert-leucine (2.5 g, 10.8 mmol), HOBT (4.2 g, 24.9 mmol), EDC (4.77 g, 24.9 mmol) and piperidine-4-carbonitrile (2.98 g, 27.0 mmol). Then added DMF (50 mL) followed by N,N-diisopropylethylamine (10.7 ml, 61.6 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with 10% citric acid and extracted with EtOAc (2*). The combined organic layers were washed twice with 10% citric acid, twice with sat'd LiCl and once with brine then dried over MgSO4, filtered and concentrated to give 3.4 g (97%) of [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester as a beige foamy solid. |
97% | With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; | Example 8. 2 -(5 -Chloro-1 -methyl- 1 H-indazol-3 -yl)-5H-pyrrolo [2,3 -b]pyrazine-7-carboxylic acid [(R)- 1 -(4- cyano-piperidine-l-carbonyl)-2,2- imeth l-propyl]-amideStep 1[(R)-l-(4-Cyano-piperidine-l-carbonyl)-2,2-dimethyl-pro l]-carbamic acid tert-butyl esterA round-bottomed flask was charged with Boc-D-tert-leucine (2.5 g, 10.8 mmol), HOBT (4.2 g, 24.9 mmol), EDC (4.77 g, 24.9 mmol) and piperidine-4-carbonitrile (2.98 g, 27.0 mmol). Then added DMF (50 mL) followed by N,N-diisopropylethylamine (10.7 ml, 61.6 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with 10% citric acid and extracted with EtOAc (2x). The combined organic layers were washed twice with 10% citric acid, twice with sat'd LiCl and once with brine then dried over MgSC^, filtered and concentrated to give 3.4 g (97%) of [(R)-l-(4-cyano-piperidine-l-carbonyl)-2,2-dimethyl- propyl]-carbamic acid tert-butyl ester as a beige foamy solid. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
95% | With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; | Step 1 A round-bottomed flask was charged with Boc-D-tert-leucine (0.30 g, 1.3 mmol, 4-hydroxy-4-phenylpiperidine (345 mg, 1.95 mmol), HOBT (218 mg, 1.43 mmol) and EDC (274 mg, 1.43 mmol). Then added DMF (6 mL) followed by N,N-diisopropylethylamine (0.34 mL, 1.95 mmol). The light yellow reaction mixture was stirred at room temperature overnight then quenched with water and extracted with diethyl ether (2*). The organic layers were combined and washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over 24 g SiO2 with 0-40% EtOAc/heptane to give 0.48 g (95%) of [(R)-1-(4-hydroxy-4-phenyl-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester as an off-white foam. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
83% | Step 2 To a solution of tert-butyl 3-cyano-3-fluoropyrrolidine-1-carboxylate (240 mg, 1.12 mmol) in CH2Cl2 (5 mL) was added TFA (2.0 mL, 26.0 mmol). The pale yellow reaction mixture was stirred at room temperature for 4 h then concentrated to a yellow oil and dried under high vacuum. In a 50 mL flask were combined the above oil (237 mg, 1.04 mmol), <strong>[124655-17-0](R)-2-(tert-butoxycarbonylamino)-3,3-dimethylbutanoic acid</strong> (200 mg, 0.87 mmol), and HOBT (146 mg, 0.95 mmol). Then added DMF (4 mL) followed by HATU (362 mg, 0.95 mmol) and N,N-diisopropylethylamine (0.45 mL, 2.59 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with H2O and extracted with EtOAc (3*). The combined organics were washed with H2O (3*) then dried over MgSO4 and concentrated. The crude residue was purified by SiO2 chromatography (20% to 50% EtOAc/hexanes) to isolate 234 mg (83%) of tert-butyl (2R)-1-(3-cyano-3-fluoropyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate as a viscous colorless oil. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
83% | With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; | Step 1 A 50 mL round-bottomed flask was charged with Boc-D-tert-leucine (1.00 g, 4.32 mmol), HOBT (728 mg, 4.76 mmol), EDC (912 mg, 4.76 mmol) and pyrrolidine (0.57 mL, 6.89 mmol). Then added DMF (18 mL) followed by N,N-diisopropylethylamine (1.1 ml, 6.3 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with H2O and extracted with Et2O (2*). The combined organic layers were washed twice with H2O and once with brine then dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography over 40 g SiO2 with EtOAc/hexanes (gradient: 0-30% EtOAc) to afford 1.0 g (83%) of (R)-tert-butyl 3,3-dimethyl-1-oxo-1-(pyrrolidin-1-yl)butan-2-ylcarbamate as an off-white solid. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
458 mg | With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 20℃; for 48h; | Example 43.2-(6-Chloro-l -methyl- 1 H-indazol-3 -yl)-5H-pyrrolo [2,3 -b]pyrazine-7-carboxylic acid [(R)- 1 -(3 - cyano-azetidine-1 -carbonyl)-2,2-dimethyl-propyl]-amideStep 1[(R)-l-(3-C ano-azetidine-l-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl esterA round-bottomed flask was charged with Boc-D-tert-leucine (300 mg, 1.3 mmol) and azetidine- 3-carbonitrile hydrochloride (231 mg, 1.95 mmol). DMF (6 ml) was added followed by N,N- diisopropylethylamine (0.68 ml, 3.9 mmol) and HATU (543 mg, 1.43 mmol). The light yellow solution was stirred at room temperature for 48 h then quenched with water and extracted with diethyl ether (2x). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated to afford 458 mg of [(R)-l-(3- cyano-azetidine-l-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester as a light yellow oil. |
[ 54895-12-4 ]
2-((tert-Butoxycarbonyl)amino)-3-methylbutanoic acid
Similarity: 0.98
[ 176504-88-4 ]
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoate
Similarity: 0.95
[ 45170-31-8 ]
N-(tert-Butoxycarbonyl)-N-methyl-L-valine
Similarity: 0.95
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :